WuXi Biologics and Oxford BioTherapeutics join forces on second bispecific program

19 January 2021

Shanghai’s WuXi Biologics (HK: 2269) and Oxford BioTherapeutics (OBT) have advanced their immuno-oncology partnership for a second time.

The UK-based firm has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology (I-O) candidate, OX003.

"This product is the second molecule with WuXiBody in our partnership, following the design of OX001/PD-L1, which is now entering pre-clinical development"Christian Rohlff, chief executive of Oxford BioTherapeutics, said: “We are pleased to extend our I-O partnership with WuXi Biologics, by combining a second bispecific antibody from WuXi Biologics’ proprietary bispecific platform with one of our leading clinical IO assets, OX003.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK